The last third of anemia drug sales comes from small- and mid-sized, independent dialysis clinics. These guys don't get the sweetheart Epogen discounts from Amgen that Davita and Fresenius enjoy today so they're probably most open (and eager) for competition. Let's say Affymax can win a third of this bucket, or $200 million.
Peginesatide sales of $330 million at the end of 2015, of which Affymax receives half, risk adjusted at 90% given the looming approval decision, discounted back by 20%, yields a net present value of $73.7 million. Apply a five-times-sales multiple and you get an Affymax enterprise value of $368 million.
Please don't take these numbers to the bank but you get the idea.
Risks to the Affymax story: Amgen is an entrenched competitor that may be more difficult than anticipated to beat. Affymax and Takeda will operate the peginesatide business through a 50-50 joint venture; I generally don't like these setups because the smaller partner (Affymax) is at a disadvantage i.e. Onyx Pharma in its Nexavar joint venture with Bayer.@HemPaddy: "Why is YMI so low profile even after showing GREAT results - Street is not buying YMI story?" Referring to YM BioSciences (YMI) as "low profile" sounds like a polite euphemism for unloved? Ignored? Distrusted? You ask a great question; unfortunately, I don't have a definitive answer. YM Bio shares at $2 have barely nudged higher since the presentation last December of strong phase II data on its myelofibrosis drug CYT387. [The '387 data, particularly the positive anemia response, were strong, right? I thought so.] When I ask buyside investors about why YM Bio seems so unloved, I get responses like these: We don't believe the anemia response data. We don't trust management given YM's poor track record. Why hasn't YM Bio been able to land a partner for '387? The company's recent financing was too dilutive. The company won't be able to enroll patients in its planned phase III study because Incyte's (INCY) Jakafi is already on the market. Who cares about a second-to-market myelofibrosis pill? Some of these concerns are silly, others more reasonable but still defensible. Whether you're a true believer in YMI and '387 or not, the valuation gap between the company and Incyte is too large to ignore. I'm not sure if or when sentiment shifts.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV